Table 3.
Responder rates for change in positive and negative syndrome scale (PANSS) total scores, across different threshold values. Responder categories are separated by set limits for the magnitude of decrease in the total PANSS score from baseline to day 42/end of treatment
| Placebo (n = 174) | Asenapine 5 mg bid (n = 173) | Asenapine 10 mg bid (n = 178) | Asenapine 5 mg bid − placebo | Asenapine 10 mg bid − placebo | |
|---|---|---|---|---|---|
| ≥20 % decrease | |||||
| Responder, n (%) | 52 (29.9) | 92 (53.2) | 91 (51.1) | 23.3 | 21.2 |
| 95 % CI (%) | 23.2, 37.3 | 45.5, 60.8 | 43.5, 58.7 | 13.2, 33.4 | 11.2, 31.2 |
| ≥30 % decrease | |||||
| Responder, n (%) | 36 (20.7) | 68 (39.3) | 78 (43.8) | 18.6 | 23.1 |
| 95 % CI (%) | 14.9, 27.5 | 32.0, 47.0 | 36.4, 51.4 | 9.2, 28.1 | 13.7, 32.6 |
| ≥40 % decrease | |||||
| Responder, n (%) | 21 (12.1) | 41 (23.7) | 56 (31.5) | 11.6 | 19.4 |
| 95 % CI (%) | 7.6, 17.9 | 17.6, 30.7 | 24.7, 38.8 | 3.7, 19.6 | 11.0, 27.8 |
| ≥50 % decrease | |||||
| Responder, n (%) | 8 (4.6) | 25 (14.5) | 40 (22.5) | 9.9 | 17.9 |
| 95 % CI (%) | 2.0, 8.9 | 9.6, 20.6 | 16.6, 29.3 | 3.8, 15.9 | 11.0, 24.8 |
bid twice daily, CI confidence interval